Investment Analysts’ Weekly Ratings Updates for Alkermes (ALKS)

Alkermes (NASDAQ: ALKS) recently received a number of ratings updates from brokerages and research firms:

• 5/6/2026 – Alkermes had its price target raised by UBS Group AG from $42.00 to $48.00. They now have a “buy” rating on the stock.
• 5/6/2026 – Alkermes had its price target raised by Wells Fargo & Company from $43.00 to $44.00. They now have an “overweight” rating on the stock.
• 5/6/2026 – Alkermes had its price target raised by Needham & Company LLC from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Alkermes was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 4/27/2026 – Alkermes was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/9/2026 – Alkermes had its price target raised by Bank of America Corporation from $34.00 to $36.00. They now have a “neutral” rating on the stock.
• 3/25/2026 – Alkermes was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/24/2026 – Alkermes had its price target lowered by Piper Sandler from $45.00 to $43.00. They now have an “overweight” rating on the stock.
• 3/20/2026 – Alkermes was downgraded by Zacks Research from “hold” to “strong sell”.

Insider Buying and Selling at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the transaction, the senior vice president owned 109,769 shares of the company’s stock, valued at $3,293,070. This represents a 5.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.20, for a total value of $67,528.80. Following the transaction, the executive vice president directly owned 231,558 shares of the company’s stock, valued at $7,687,725.60. The trade was a 0.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 39,102 shares of company stock valued at $1,265,090 in the last 90 days. Insiders own 4.59% of the company’s stock.

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.